Thomas Kolben1, Udo Jeschke2, Toralf Reimer3, Nora Karsten2, Elisa Schmoeckel4, Anna Semmlinger2, Sven Mahner2, Nadia Harbeck2, Theresa M Kolben2. 1. Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians-University Munich, Marchioninistr. 15, 81377, Munich, Germany. Thomas.Kolben@med.uni-muenchen.de. 2. Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians-University Munich, Marchioninistr. 15, 81377, Munich, Germany. 3. Department of Obstetrics and Gynecology, University of Rostock, Suedring 81, 18059, Rostock, Germany. 4. Department of Pathology, Ludwig-Maximilians-University Munich, Marchioninistr. 15, 81377, Munich, Germany.
Abstract
PURPOSE: The Fas-antigen is a cell surface receptor that transduces apoptotic signals into cells. The purpose of this study was to evaluate FasL expression in breast cancer and to elucidate the role of its signaling in different breast cancer cell lines. METHODS: T47D and MCF7 cells were used and cultured in Dulbecco's modified Eagle's medium. FasL translocation to the membrane was achieved by culturing the cells in the presence of human interferon-γ (IFNγ). Translocation was detected by immunofluorescence. The ability of a Fas:Fc fusion protein to trigger apoptosis in these cells was investigated by cell death detection ELISA. After incubation with IFNγ for 4 h and 18 h, apoptosis was assessed in response to treatment with Fas:Fc. RESULTS: Immunofluorescence revealed that the used cell lines were positive for FasL which was increased and changed to more membrane-bound FasL expression after IFNγ stimulation. After stimulation with 50 IU/ml IFNγ, Fas:Fc significantly increased MCF7 apoptosis (1.39 ± 0.06-fold, p = 0.0004) after 18 h. After stimulation with 100 IU/ml, Fas:Fc significantly increased apoptosis both after 4 h (1.49 ± 0.15-fold, p = 0.018) and 18 h (1.30 ± 0.06-fold, p = 0.013). In T47D cells this effect was seen after 4 h of stimulation with 50 IU/ml and addition of Fas:Fc (1.6 ± 0.08-fold, p = 0.03). CONCLUSION: Membrane-bound FasL expression could be induced by IFNγ in a breast cancer cell model. More importantly, in the presence of IFNγ the Fas:Fc fusion protein was able to transmit pro-apoptotic signals to T47D and MCF7 cells, significantly inducing apoptosis. The current findings support further in vivo studies regarding FasL activation as a potential target for therapeutic intervention in breast cancer.
PURPOSE: The Fas-antigen is a cell surface receptor that transduces apoptotic signals into cells. The purpose of this study was to evaluate FasL expression in breast cancer and to elucidate the role of its signaling in different breast cancer cell lines. METHODS: T47D and MCF7 cells were used and cultured in Dulbecco's modified Eagle's medium. FasL translocation to the membrane was achieved by culturing the cells in the presence of human interferon-γ (IFNγ). Translocation was detected by immunofluorescence. The ability of a Fas:Fc fusion protein to trigger apoptosis in these cells was investigated by cell death detection ELISA. After incubation with IFNγ for 4 h and 18 h, apoptosis was assessed in response to treatment with Fas:Fc. RESULTS: Immunofluorescence revealed that the used cell lines were positive for FasL which was increased and changed to more membrane-bound FasL expression after IFNγ stimulation. After stimulation with 50 IU/ml IFNγ, Fas:Fc significantly increased MCF7 apoptosis (1.39 ± 0.06-fold, p = 0.0004) after 18 h. After stimulation with 100 IU/ml, Fas:Fc significantly increased apoptosis both after 4 h (1.49 ± 0.15-fold, p = 0.018) and 18 h (1.30 ± 0.06-fold, p = 0.013). In T47D cells this effect was seen after 4 h of stimulation with 50 IU/ml and addition of Fas:Fc (1.6 ± 0.08-fold, p = 0.03). CONCLUSION: Membrane-bound FasL expression could be induced by IFNγ in a breast cancer cell model. More importantly, in the presence of IFNγ the Fas:Fc fusion protein was able to transmit pro-apoptotic signals to T47D and MCF7 cells, significantly inducing apoptosis. The current findings support further in vivo studies regarding FasL activation as a potential target for therapeutic intervention in breast cancer.
Entities:
Keywords:
Apoptosis; Breast cancer; Fas ligand; FasL reverse signaling
Authors: Marcus E Peter; Ralph C Budd; Julie Desbarats; Stephen M Hedrick; Anne-Odile Hueber; M Karen Newell; Laurie B Owen; Richard M Pope; Juerg Tschopp; Harald Wajant; David Wallach; Robert H Wiltrout; Martin Zörnig; David H Lynch Journal: Cell Date: 2007-05-04 Impact factor: 41.582
Authors: K Connolly; Y H Cho; R Duan; J Fikes; T Gregorio; D W LaFleur; Z Okoye; T W Salcedo; G Santiago; S Ullrich; P Wei; K Windle; E Wong; X T Yao; Y Q Zhang; G Zheng; P A Moore Journal: J Pharmacol Exp Ther Date: 2001-07 Impact factor: 4.030
Authors: M Mottolese; S Buglioni; C Bracalenti; M A Cardarelli; L Ciabocco; D Giannarelli; C Botti; P G Natali; A Concetti; F M Venanzi Journal: Int J Cancer Date: 2000-03-20 Impact factor: 7.396
Authors: Erik J Blok; Jitske van den Bulk; N Geeske Dekker-Ensink; Remco Derr; Corné Kanters; Esther Bastiaannet; Judith R Kroep; Cornelis J H van de Velde; Peter J K Kuppen Journal: Oncotarget Date: 2017-02-28
Authors: Bradley D Johnson; Ziwen Zhu; Marco Lequio; Coby G D Powers; Qian Bai; Huaping Xiao; Emerson Fajardo; Mark R Wakefield; Yujiang Fang Journal: Med Oncol Date: 2022-01-20 Impact factor: 3.738